Results 181 to 190 of about 1,466,333 (379)

The regulatory effects and applications of TIGIT/CD155 on the tumor microenvironment in HCC

open access: yesVIEW, EarlyView.
Background The interaction between TIGIT and CD155 compromises immune cell efficacy in tumor targeting, potentially driving hepatocellular carcinoma (HCC) progression through diverse molecular pathways. What Was Done This study investigates the interplay between CD155 and TIGIT in regulating CD8+ T cell function and elucidates its implications in HCC ...
Wenting Li   +10 more
wiley   +1 more source

Lysis of Prostate Carcinoma Cells by Trifunctional Bispecific Antibodies (αEpCAM × αCD3) [PDF]

open access: bronze, 2001
Rainer Riesenberg   +3 more
openalex   +1 more source

Dual Inhibition of Mast Cells and Thymic Stromal Lymphopoietin Using a Novel Bispecific Antibody, CDX‐622

open access: yesAllergy, EarlyView.
SCF and TSLP expression are known to drive unique immune responses leading to the onset of allergic and inflammatory diseases. Here, we describe the characterization of a novel bsAb, CDX‐622, that targets SCF and TSLP. CDX‐622 inhibits MC functions through SCF starvation and Type 2 inflammatory responses via TSLP inhibition.
Michael B. Murphy   +17 more
wiley   +1 more source

Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy

open access: yesInternational Journal of Nanomedicine, 2018
Haitao Pan,1,2 Jiayu Liu,1,2 Wentong Deng,1,2 Jieyu Xing,1,2 Qing Li,1,2 Zhong Wang1,2 1School of Pharmaceutical Sciences, 2Centre for Cellular & Structural Biology, Sun Yat-Sen University, Guangzhou, People’s Republic of China Introduction ...
Pan H   +5 more
doaj  

Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non‐Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group

open access: yesBritish Journal of Haematology, EarlyView.
Summary Developing new therapeutic regimens for relapsed/refractory (R/R) B non‐Hodgkin lymphoma (NHL) patients remains a significant unmet clinical need. Our objective was to evaluate atezolizumab (ATE), obinutuzumab (OBI) and venetoclax (VEN) combination in patients with R/R NHL who had received at least one prior anti‐CD20‐containing ...
Charles Herbaux   +21 more
wiley   +1 more source

Design of a humanized CD40 agonist antibody with specific properties using AlphaFold2 and development of an anti-PD-L1/CD40 bispecific antibody for cancer immunotherapy

open access: yesTranslational Oncology
Bispecific antibodies (BsAbs) represent a promising strategy for cancer immunotherapy. Challenges in immunotherapy include inefficient early events in the immune response cycle, such as antigen presentation and T cell priming.
Kun Du, He Huang
doaj  

The role of blinatumomab in adult acute B lymphoblastic leukaemia

open access: yesBritish Journal of Haematology, EarlyView.
Blinatumomab, a CD19‐directed bispecific T‐cell engager, has become a crucial part of BCP‐ALL therapy in r/r disease, MRD‐positive disease and has recently been implemented into first‐line therapy of BCP‐ALL. This review discusses important clinical trials with a focus on blinatumomab in first‐line therapy of adult BCP‐ALL.
Anne C. Wilke, Nicola Gökbuget
wiley   +1 more source

Natural Killer Cells in Cancer Immunotherapy [PDF]

open access: yes, 2019
Arndt MA   +15 more
core   +1 more source

Bispecific Monoclonal Antibodies Mediate Binding of Dengue Virus to Erythrocytes in a Monkey Model of Passive Viremia [PDF]

open access: bronze, 2001
Chang S. Hahn   +4 more
openalex   +1 more source

Home - About - Disclaimer - Privacy